- Home
- AGL vs ANIP Comparison
AGL vs ANIP Comparison
Compare AGL & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGL
- ANIP
- Stock Information
- Founded
- AGL 2016
- ANIP 2001
- Country
- AGL United States
- ANIP United States
- Employees
- AGL N/A
- ANIP N/A
- Industry
- AGL Managed Health Care
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- AGL Health Care
- ANIP Health Care
- Exchange
- AGL Nasdaq
- ANIP Nasdaq
- Market Cap
- AGL 1.4B
- ANIP 1.2B
- IPO Year
- AGL 2021
- ANIP N/A
- Fundamental
- Price
- AGL $3.53
- ANIP $57.94
- Analyst Decision
- AGL Hold
- ANIP Buy
- Analyst Count
- AGL 18
- ANIP 7
- Target Price
- AGL $4.03
- ANIP $77.33
- AVG Volume (30 Days)
- AGL 5.1M
- ANIP 172.8K
- Earning Date
- AGL 02-25-2025
- ANIP 02-28-2025
- Dividend Yield
- AGL N/A
- ANIP N/A
- EPS Growth
- AGL N/A
- ANIP N/A
- EPS
- AGL N/A
- ANIP N/A
- Revenue
- AGL $5,594,117,000.00
- ANIP $555,456,000.00
- Revenue This Year
- AGL $41.67
- ANIP $25.54
- Revenue Next Year
- AGL $8.85
- ANIP $20.95
- P/E Ratio
- AGL N/A
- ANIP N/A
- Revenue Growth
- AGL 54.10
- ANIP 23.60
- 52 Week Low
- AGL $1.50
- ANIP $52.50
- 52 Week High
- AGL $7.73
- ANIP $70.81
- Technical
- Relative Strength Index (RSI)
- AGL 59.38
- ANIP 46.25
- Support Level
- AGL $3.32
- ANIP $58.37
- Resistance Level
- AGL $3.73
- ANIP $60.54
- Average True Range (ATR)
- AGL 0.24
- ANIP 1.69
- MACD
- AGL -0.03
- ANIP -0.21
- Stochastic Oscillator
- AGL 54.40
- ANIP 20.28
About AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.